- Home
- MANH vs EXAS Comparison
MANH vs EXAS Comparison
Compare MANH & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MANH
- EXAS
- Stock Information
- Founded
- MANH 1990
- EXAS 1995
- Country
- MANH United States
- EXAS United States
- Employees
- MANH N/A
- EXAS N/A
- Industry
- MANH Computer Software: Prepackaged Software
- EXAS Medical Specialities
- Sector
- MANH Technology
- EXAS Health Care
- Exchange
- MANH Nasdaq
- EXAS Nasdaq
- Market Cap
- MANH 10.3B
- EXAS 8.8B
- IPO Year
- MANH 1998
- EXAS N/A
- Fundamental
- Price
- MANH $167.52
- EXAS $45.89
- Analyst Decision
- MANH Strong Buy
- EXAS Strong Buy
- Analyst Count
- MANH 10
- EXAS 17
- Target Price
- MANH $266.78
- EXAS $71.75
- AVG Volume (30 Days)
- MANH 1.1M
- EXAS 2.5M
- Earning Date
- MANH 04-22-2025
- EXAS 02-19-2025
- Dividend Yield
- MANH N/A
- EXAS N/A
- EPS Growth
- MANH 24.47
- EXAS N/A
- EPS
- MANH 3.51
- EXAS N/A
- Revenue
- MANH $1,042,352,000.00
- EXAS $2,758,867,000.00
- Revenue This Year
- MANH $4.28
- EXAS $13.02
- Revenue Next Year
- MANH $8.56
- EXAS $13.02
- P/E Ratio
- MANH $47.74
- EXAS N/A
- Revenue Growth
- MANH 12.23
- EXAS 10.37
- 52 Week Low
- MANH $164.48
- EXAS $40.62
- 52 Week High
- MANH $312.60
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- MANH 28.26
- EXAS 34.94
- Support Level
- MANH $164.48
- EXAS $45.80
- Resistance Level
- MANH $173.55
- EXAS $50.17
- Average True Range (ATR)
- MANH 5.25
- EXAS 2.55
- MACD
- MANH 2.01
- EXAS -0.14
- Stochastic Oscillator
- MANH 13.64
- EXAS 19.30
About MANH Manhattan Associates Inc.
Manhattan Associates Inc provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers around the world.
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.